Genentech reports positive results from Phase III CLEOPATRA study
03:05 EDT 25 Jun 2012 | Pharmaceutical Business Review
Genentech has announced positive data from CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) study which evaluated the efficacy and safety of Perjeta combined with Herceptin and docetaxel chemotherapy compared to Herceptin and chemotherap..
Original Article: Genentech reports positive results from Phase III CLEOPATRA study
More From BioPortfolio on "Genentech reports positive results from Phase III CLEOPATRA study"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
